Search research articles
Contact Us
Filters
Showing results (1-10 of 35) with videos related to
Page
of 4
Sort By:
Proteome Science
|
June 21, 2005
Cognate peptide-receptor ligand mapping by directed phage display
Thomas Stratmann, Angray S Kang
Human Antibodies
|
June 21, 2021
Immunogenicity of biologics used in the treatment of moderate to severe psoriasis
Visha Patel, Alex Efimov, David Baker, et al.
Experimental Parasitology
|
March 9, 2010
Trypanosoma cruzi: synergistic cytotoxicity of multiple amphipathic anti-microbial peptides to T. cruzi and potential bacterial hosts
Annabeth Fieck, Ivy Hurwitz, Angray S Kang, et al.
Human Antibodies
|
December 16, 2004
IgG(4) Pf NPNA-1 a human anti-Plasmodium falciparum sporozoite monoclonal antibody cloned from a protected individual inhibits parasite invasion of hepatocytes
Jonathan A Chappel, Michael R Hollingdale, Angray S Kang
Human Antibodies
|
June 21, 2021
Immunogenicity of biologics used in the treatment of inflammatory bowel disease
Mariam Bqain, Alex Efimov, David Baker, et al.
Multiple Sclerosis and Related Disorders
|
January 5, 2024
Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis
David Baker, Angray S Kang, Gavin Giovannoni, et al.
Journal of Immunological Methods
|
November 9, 2010
Module based antibody engineering: a novel synthetic REDantibody
Anatoliy Markiv, Bernard Anani, Ravi V Durvasula, et al.
Signal Transduction and Targeted Therapy
|
July 4, 2020
Mapping the T cell response to COVID-19
Junwei Li, Junhua Wang, Angray S Kang, et al.
Biochemistry
|
March 30, 2023
Exploring the "N-Terminal Anchor" Binding Interface of the T3SS Chaperone-Translocator Complexes from <i>P. aeruginosa</i>
Charlotte L Frankling, Angray S Kang, Ewan R G Main
Multiple Sclerosis and Related Disorders
|
May 29, 2020
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
David Baker, Sandra Amor, Angray S Kang, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 35) with videos related to
Sort By:
Page
of 4
Proteome Science
|
June 21, 2005
Cognate peptide-receptor ligand mapping by directed phage display
Thomas Stratmann, Angray S Kang
Human Antibodies
|
June 21, 2021
Immunogenicity of biologics used in the treatment of moderate to severe psoriasis
Visha Patel, Alex Efimov, David Baker, et al.
Experimental Parasitology
|
March 9, 2010
Trypanosoma cruzi: synergistic cytotoxicity of multiple amphipathic anti-microbial peptides to T. cruzi and potential bacterial hosts
Annabeth Fieck, Ivy Hurwitz, Angray S Kang, et al.
Human Antibodies
|
December 16, 2004
IgG(4) Pf NPNA-1 a human anti-Plasmodium falciparum sporozoite monoclonal antibody cloned from a protected individual inhibits parasite invasion of hepatocytes
Jonathan A Chappel, Michael R Hollingdale, Angray S Kang
Human Antibodies
|
June 21, 2021
Immunogenicity of biologics used in the treatment of inflammatory bowel disease
Mariam Bqain, Alex Efimov, David Baker, et al.
Multiple Sclerosis and Related Disorders
|
January 5, 2024
Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis
David Baker, Angray S Kang, Gavin Giovannoni, et al.
Journal of Immunological Methods
|
November 9, 2010
Module based antibody engineering: a novel synthetic REDantibody
Anatoliy Markiv, Bernard Anani, Ravi V Durvasula, et al.
Signal Transduction and Targeted Therapy
|
July 4, 2020
Mapping the T cell response to COVID-19
Junwei Li, Junhua Wang, Angray S Kang, et al.
Biochemistry
|
March 30, 2023
Exploring the "N-Terminal Anchor" Binding Interface of the T3SS Chaperone-Translocator Complexes from <i>P. aeruginosa</i>
Charlotte L Frankling, Angray S Kang, Ewan R G Main
Multiple Sclerosis and Related Disorders
|
May 29, 2020
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
David Baker, Sandra Amor, Angray S Kang, et al.
Page
of 4